The Second Affiliated Hospital of Harbin Medical University, No.246 Xuefu Street Nangang Block, 150081, Harbin, Heilongjiang Province, P.R. of China.
Yanda Lu Daopei Hospital, Yanjiao Economic Development Zone, 101118, Sanhe, Langfang, Hebei Province, P.R. of China.
BMC Cancer. 2023 Jul 5;23(1):630. doi: 10.1186/s12885-023-11084-x.
Multiple myeloma is a heterogeneous disorder and the intratumor genetic heterogeneity contributes to emergency of drug resistance. Dexamethasone has been used clinically for decades for MM. Nevertheless, their use is severely hampered by the risk of developing side effects and the occurrence of Dex resistance. LncRNA NEAT1 plays a oncogenic role and participates in drug resistance in many solid tumors. Therefore, we investigated a potential usefulness of this molecular as a biomarker for diagnosis of MM and possible correlations of NEAT1 expression with drug resistance and prognosis.
Bone marrow and peripheral blood mononuclear cells samples were collected from 60 newly diagnosed MM patients. The expression of NEAT1expression level were detected by quantitative real-time PCR analyses. The relationship about the expression levels of lncRNA with other clinical and cytogenetic features was analyzed. In addition, we measured to analysis the correlation between the expression of NEAT1 and Dex resistance in MM patients.
It was found that the expression of NEAT1 is significantly higher in multiple myeloma patients compared to controls and does not change with other clinical features and cytogenetic features. We further discovered that overexpression of NEAT1 was associated with Dex resistance and a poor prognosis in MM patients.
LncRNA NEAT1 has a significant value that might act as a promoting factor in the development of MM and may be severed as a diagnostic factor in MM. NEAT1 invovled in Dex resistance, which provide a new interpretation during the chemotherapy for MM.
多发性骨髓瘤是一种异质性疾病，肿瘤内遗传异质性导致耐药性的产生。地塞米松已在临床上用于 MM 数十年。然而，由于发生副作用和地塞米松耐药的风险，它们的使用受到严重阻碍。LncRNA NEAT1 在许多实体肿瘤中发挥致癌作用并参与耐药性。因此，我们研究了这种分子作为 MM 诊断的生物标志物的潜在用途，以及 NEAT1 表达与耐药性和预后的可能相关性。
收集 60 例新诊断的 MM 患者的骨髓和外周血单个核细胞样本。通过定量实时 PCR 分析检测 NEAT1 表达水平。分析 lncRNA 的表达水平与其他临床和细胞遗传学特征之间的关系。此外，我们还测量了 MM 患者中 NEAT1 表达与地塞米松耐药之间的相关性。
研究发现，与对照组相比，多发性骨髓瘤患者中 NEAT1 的表达显着升高，并且与其他临床特征和细胞遗传学特征无关。我们进一步发现，NEAT1 的过表达与 MM 患者的地塞米松耐药和不良预后相关。
LncRNA NEAT1 具有重要价值，可能作为 MM 发生的促进因素，并可作为 MM 的诊断因素。NEAT1 参与地塞米松耐药，为 MM 化疗提供了新的解释。
